Free Trial
→ 2025: Digital Asset Insights You Need to Know (From Darwin) (Ad)

Will the Biotech sector sustain its momentum in 2024?

Ryan Hasson
Written by Ryan Hasson | Reviewed by Don Miller
January 4, 2024

Key Points

  • Biotech's iShares ETF (IBB) experienced a near 4% upswing on the year's first trading day, outshining struggling sectors.
  • The IBB ETF now faces critical resistance at $138 after a robust three-month climb.
  • AMGN, VRTX, and GILD, the top holdings in the ETF, significantly impact the sector's direction based on their individual performances.
  • 5 stocks we like better than iShares Biotechnology ETF.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should you invest $1,000 in iShares Biotechnology ETF right now?

Before you consider iShares Biotechnology ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iShares Biotechnology ETF wasn't on the list.

While iShares Biotechnology ETF currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover
Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Learn More about Ryan Hasson
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Amgen (AMGN)
4.7935 of 5 stars		$278.260.0%3.23%35.63Hold$323.05
Gilead Sciences (GILD)
4.675 of 5 stars		$91.59-1.0%3.36%1,017.67Moderate Buy$95.41
Vertex Pharmaceuticals (VRTX)
4.2669 of 5 stars		$463.98+1.5%N/A-233.16Moderate Buy$504.38
iShares Biotechnology ETF (IBB)N/A$140.96+0.7%0.32%N/AModerate Buy$140.96
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

2025 Gold Forecast: A Perfect Storm for Demand and New Highs
Former Trump Advisor: Expect REITs to Soar Under Trump’s Next Presidency
Super Micro’s Rebound: Can SMCI Stock Rally Another 100%?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines